A detailed history of Synovus Financial Corp transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Synovus Financial Corp holds 53,071 shares of CLSD stock, worth $54,663. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,071
Previous 53,071 -0.0%
Holding current value
$54,663
Previous $68,000 1.47%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$1.2 - $2.02 $6,000 - $10,100
-5,000 Reduced 8.61%
53,071 $81,000
Q1 2023

May 11, 2023

SELL
$0.93 - $1.66 $6,305 - $11,254
-6,780 Reduced 10.45%
58,071 $60,000
Q2 2022

Aug 10, 2022

SELL
$1.3 - $2.49 $13,000 - $24,900
-10,000 Reduced 13.36%
64,851 $95,000
Q1 2022

May 12, 2022

BUY
$1.35 - $2.88 $63,153 - $134,726
46,780 Added 166.65%
74,851 $171,000
Q4 2020

Feb 11, 2021

BUY
$1.32 - $2.74 $37,053 - $76,914
28,071 New
28,071 $77,000
Q4 2019

Feb 06, 2020

SELL
$0.62 - $3.4 $3,100 - $17,000
-5,000 Closed
0 $0
Q4 2018

Feb 07, 2019

SELL
$1.0 - $6.12 $500 - $3,060
-500 Reduced 9.09%
5,000 $5,000
Q1 2018

May 07, 2018

BUY
$5.57 - $14.28 $30,635 - $78,540
5,500 New
5,500 $59,000

Others Institutions Holding CLSD

About Clearside Biomedical, Inc.


  • Ticker CLSD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,190,700
  • Market Cap $62M
  • Description
  • Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...
More about CLSD
Track This Portfolio

Track Synovus Financial Corp Portfolio

Follow Synovus Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Synovus Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Synovus Financial Corp with notifications on news.